Display options
Cite
Kamal MA, Gieschke R, Lemenuel-Diot A, et al. Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression. Antimicrob Agents Chemother. 2016;60(3):1953doi: 10.1128/AAC.00179-16.
Kamal, M. A., Gieschke, R., Lemenuel-Diot, A., Beauchemin, C. A., Smith, P. F., & Rayner, C. R. (2016). Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression. Antimicrobial agents and chemotherapy, 60(3), 1953. https://doi.org/10.1128/AAC.00179-16
Kamal, Mohamed A, et al. "Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression." Antimicrobial agents and chemotherapy vol. 60,3 (2016): 1953. doi: https://doi.org/10.1128/AAC.00179-16
Kamal MA, Gieschke R, Lemenuel-Diot A, Beauchemin CA, Smith PF, Rayner CR. Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression. Antimicrob Agents Chemother. 2016 Feb 26;60(3):1953. doi: 10.1128/AAC.00179-16. Print 2016 Mar. PMID: 26921415; PMCID: PMC4775932.
Copy Download .nbib Format: NLM
Share it on

Antimicrob Agents Chemother. 2016 Feb 26;60(3):1953. doi: 10.1128/AAC.00179-16. Print 2016 Mar.

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.

Antimicrobial agents and chemotherapy

Mohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, Catherine A A Beauchemin, Patrick F Smith, Craig R Rayner

Affiliations

  1. Department of Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, New York City, New York, USA.
  2. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  3. Department of Physics, Ryerson University, Toronto, Ontario, Canada.
  4. Monash Institute of Pharmaceutical Sciences, Melbourne, Australia d3 Medicine LLC, Parsippany, New Jersey, USA.
  5. Monash Institute of Pharmaceutical Sciences, Melbourne, Australia University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.

PMID: 26921415 PMCID: PMC4775932 DOI: 10.1128/AAC.00179-16

[No abstract available.]

Publication Types